课题基金 / 基金详情

PHASE I/II OPEN-LABEL PHARMACOKINETIC AND SAFETY STUDY OF ZENAPAX

PHASE I/II OPEN-LABEL PHARMACOKINETIC AND SAFETY STUDY OF ZENAPAX
Zenapax 的 I/II 期开放标签药代动力学和安全性研究
批准号：
6118435
负责人：
ROBERT Bruce ETTENGER
金额：
$0.19万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6118435
关键词：
acute disease /disorder chronic disease /disorder chronic renal failure clinical research clinical trial phase I dialysis therapy drug screening /evaluation homologous transplantation human subject human therapy evaluation immunosuppressive kidney transplantation pharmacokinetics transplant rejection

项目摘要

项目成果

ROBERT Bruce ETTENGER的其他基金

相关文献

中文摘要
翻译
肾移植是治疗终末期肾病的首选方法。同种异体移植排斥反应治疗的进步提高了患者和移植物的存活率。然而，急性和慢性排斥反应都继续阻碍移植物的存活。一年后，约80%的移植物存活，约一半存活至8年。失败的移植物需要透析，并在可能的情况下再次移植。移植存活的延长有效地增加了相对于需求的器官供应。
英文摘要
Kidney transplantation is the treatment of choice for end stage renal disease. Advances in the treatment of allograft rejection have increased the survival of both patients and their grafts. Nevertheless acute and chronic rejection both continue to hamper graft survival. At one year, about 80% of grafts survive about half survive to 8 years. Failed grafts require dialysis and retransplantation when possible. Prolongation of graft survival effectively increases the supply of organs relative to demand.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A RANDOMIZED, MULTI-CENTER COMPARATIVE TRIAL OF TACROLIMUS WITH STEROIDS AND
A RANDOMIZED, MULTI-CENTER COMPARATIVE TRIAL OF TACROLIMUS WITH STEROIDS AND
A RANDOMIZED, MULTI-CENTER COMPARATIVE TRIAL OF TACROLIMUS WITH STEROIDS AND
PHASE I/II OPEN-LABEL PHARMACOKINETIC AND SAFETY STUDY OF ZENAPAX